{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-296630","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.410555+00:00","generated_at":"2026-06-07T11:59:59.849940+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Phathom amends bylaws to adopt universal proxy rules and enhance stockholder nomination disclosures","bullets":["Amended bylaws require compliance with SEC Rule 14a-19 for proxy solicitations supporting non-Board nominees.","Enhanced disclosure requirements for stockholders nominating directors or submitting proposals at meetings.","Changes effective December 13, 2023; also includes technical and modernizing updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-296630","json":"https://secwatch.observer/filing/0001193125-23-296630.json","markdown":"https://secwatch.observer/filing/0001193125-23-296630.md","text":"https://secwatch.observer/filing/0001193125-23-296630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523296630/0001193125-23-296630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523296630/d602391d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:59:59.849940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcb199eb564d6c51202b7671c77e1e36fe46d0b4","claim":"Phathom Pharmaceuticals, Inc.: Amended and restated bylaws to address universal proxy rules, enhance procedural mechanics for stockholder nominations and proposals, and make technical updates (effective 2023-12-13).","evidence_excerpt":"On December 13, 2023, the Board of Directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523296630/0001193125-23-296630-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-13"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}